Introduction: The antidepressive effect of racemic citalopram (CIT) is exerted by S-CIT, while R-CIT is a partial antagonist to S-CIT. Since R-and S-CIT are metabolized by different pathways, we investigated whether the ratio of S- and R-CIT may differ between individuals on the same dose of racemic CIT, and if a possible variability in the R/S-ratio could be dose-dependent.
Methods: A chiral analysis of R- and S-CIT in serum samples taken from 88 female patients receiving treatment with racemic CIT was performed using high-pressure liquid chromatography.
Results: The mean levels of R-CIT were significantly higher than those of S-CIT in all dose groups. The R/S-CIT ratio increased from 1.99 to 2.45 with an increase in the dose (p<0.05), and the interindividual variance in the R/S-CIT ratio was up to four-fold on the same dosage.
Discussion: Our findings show that the stereoselective metabolism of citalopram in vivo has pharmacokinetic consequences reflected by dose dependent variations of enantiomeric drug concentrations, as well as substantial interindividual variabilities in the ratios of the concentrations. The clinical consequences, however, are unclear and should be further explored.
References
1
Auquier P, Robitail S, Llorca PM. et al .
Comparison of escitalopram and citalopram efficacy: a meta- analysis.
Int J Psychiatry Clin Pract.
2003;
7
259-268
7
Danish University Antidepressant Group
.
Citalopram: clinical effect profile in comparison with clomipramine. A controlled multicenter study.
Psychopharmacology.
1986;
90
131-138
8
Dufour H, Bouchacourt M, Thermoz P. et al .
Citalopram – a highly selective 5-HT uptake inhibitor in the treatment of depressed patients.
lnt Clin Psychopharmacol.
1987;
2
225-237
9
El Mansari M, Wiborg O, Mnie-Filali O. et al .
Allosteric modulation of the effect of escitalopram, paroxetine and fluoxetine: In-vitro and in-vivo studies.
Int J Neuropsychopharmacol.
2007;
10
31-40
10
Gorman JM, Korotzer A, Su G.
Efficacy comparison of escitalopram and citalopram in the treatment of major depressive disorder: pooled analysis of placebo-controlled trials.
CNS Spectr.
2002;
7
40-44
11
Hogg S, Sanchez C.
The antidepressant effects of citalopram are mediated by the S-((+))- and not the R-(−) enantiomer.
Eur Neuropsychopharmacol.
1999;
9
(S 01)
S213
13
Hyttel J, Bøgesø KP, Perregaard J. et al .
The pharmacological effect of citalopram residues in the (S)-(+)-enantiomer.
J Neural Transm.
1992;
88
157-160
14
Kasper S, Sacher J, Klein. et al .
Differences in the dynamics of serotonin reuptake transporter occupancy may explain superior clinical efficacy of escitalopram versus citalopram.
Int Clin Psychopharmacol.
2009;
24
119-125
15
Kosel M, Amey M, Aubert A-C. et al .
In vitro metabolism of citalopram by monoamine oxidase B in human blood.
Eur Neuropsychopharmacol.
2001;
11
75-78
16
Kosel M, Gnerre C, Voirol P. et al .
In vitro biotransformation of the selective serotonin reuptake inhibitor, citalopram, its enantiomers and demethylated metabolites by monoamine oxidase in rat and human brain preparations.
Mol Psychiatry.
2002;
7
181-188
17
Le Bloc`h Y, Woggon B, Weissenrieder H. et al .
Routine therapeutic drug monitoring in patients treated with 10–360 mg/day Citalopram.
Ther Drug Monit.
2003;
25
600-608
18
Lepola U, Wade A, Andersen HF.
Do equivalent doses of escitalopram and citalopram have similar efficacy? A pooled analysis of two positive placebo-controlled studies in major depressive disorder.
Int Clin Psychopharmacol.
2004;
19
149-155
19
Llorca PM, Azorin JM, Despiegel N. et al .
Efficacy of escitalopram in patients with severe depression: a pooled analysis.
Int J Clin Pract.
2005;
59
268-274
20
Moore N, Verdoux H, Fantino B.
Prospective, multicentre, randomized, double-blind study of the efficacy of escitalopram versus citalopram in outpatient treatment of major depressive disorder.
Int Clin Psychopharmacol.
2005;
20
131-137
21
Nikisch G, Mathe AA, Czernik A. et al .
Stereoselective metabolism of citalopram in plasma and cerebrospinal fluid of depressed patients.
J Clin Psychopharmacol.
2004;
24
283-290
22
Rasmussen B, Brøsen K.
Is therapeutic drug monitoring a case for optimizing clinical outcome and avoiding interactions of the selective serotonin reuptake inhibitors?.
Ther Drug Monit.
2000;
22
143-154
23
Rochat B, Amey M, Gillet M. et al .
Identification of three cytochrome P450 isoenzymes involved in N-demethylation of citalopram enantiomers in human liver microsomes.
Pharmacogenetics.
1997;
7
1-10
24
Rochat B, Kosel M, Boss G. et al .
Stereoselective biotransformation of the selective serotonin reuptake inhibitor, citalopram, and its demethylated metabolites by monoamine oxidase in human liver.
Biochem Pharmacol.
1998;
56
15-23
25
Sanchez C, Bøgesø KP, Ebert B. et al .
Escitalopram versus citalopram: the surprising role of the R-enantiomer.
Psychopharmacology.
2004;
174
163-176
26
Sidhu J, Priskorn M, Poulsen M. et al .
Steady-state pharmacokinetics of the enantiomers of citalopram and its metabolites in humans.
Chirality.
1997;
9
686-692
28
Uhr M, Grauer MT.
abcb1 ab P-Glycoprotein is involved in the uptake of citalopram and trimipramine into the brain of mice.
J Psychiatr Res.
2003;
37
179-185
29
von Moltke LL, Greenblatt DJ, Giancarlo GM. et al .
Escitalopram (S-citaopram) and its metabolites in vitro: cytochromes mediating biotransformation, inhibitory effects, and comparison to R-citalopram.
Drug Metab Dispos.
2001;
29
1102-1109
30
Zhong H, Hansen KB, Boyle NJ. et al .
An allosteric binding site at the human serotonin transporter mediates the inhibition of escitalopram by R-citalopram: kinetic binding studies with the ALI/VFL-SI/TT mutant.
Neurosci Lett.
2009;
462
207-212
